The objective of this study is to evaluate the risk of inflammatory disease activity by retrospectively comparing two therapeutic strategies (escalation group and induction group). The investigators also aim to identify factors associated with inflammatory relapse and treatment-related complications.
Patients with RRMS onset after age 50
Patients who started their first disease-modifying therapy within 2 years of the first symptoms
Patients Treated with moderately effective disease-modifying antirheumatic drugs (DMARDs) (teriflunomide, dimethyl fumarate or diroximel fumarate, glatiramer acetate, interferon beta, peginterferon)
Patient treated with highly effective DMARDs (fingolimod, ponesimod, natalizumab, rituximab, ocrelizumab, ofatumumab, cladribine)
None
Patients with RRMS onset after age 50
Case-control
Retrospective
Not listed
Time to First Clinical Inflammatory Relapse
Compare the time to first clinical inflammatory relapse between two groups of patients who developed relapsing-remitting MS (RRMS) after age 50: * Group 1 = therapeutic escalation strategy: starting with a moderately effective treatment (teriflunomide, dimethyl fumarate or diroximel fumarate, glatiramer acetate, interferon beta, peginterferon) * Group 2 = induction strategy: starting with a highly effective treatment (fingolimod, ponesimod, natalizumab, rituximab, ocrelizumab, ofatumumab, cladribine)
Click on the lead sponsor to view all of their trials.
